Clinical trials: Streptococcal Pneumonia
Pneumonia, Pneumonia - Bacterial
Urine Pneumococcal Antigen Project
Background: Pneumonia caused by the bacteria Streptococcus pneumoniae is a leading cause of death among children under five years of age, especially in sub-Saharan Africa.
- Trial name
- UPAP (NCT07181200)
- Where
- Malawi
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Pneumonia, Pneumococcal, Myocardial Ischemia
Myocardial Injury and Severe Pneumococcal Pneumonia
Hypothesis: The "novo" cardiovascular events (CVE)in patients with severe community-acquired pneumonia (CAP) are frequent (17%) and could be associated with both direct pneumococcal myocardial invasion, toxin delivery…
- Trial name
- NEUMOCAR (NCT03058211)
- Testing
- Echocardiography, Cardiac Magnetic resonance
- Where
- Spain
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Alejandro Rodriguez Oviedo , MD
Community-acquired Pneumonia
Description of Pneumococcal Pneumonia
Statement of the problem: Overprescription of antibiotics raises important public health issues because of the emergence of multiresistant bacteria by selection pressure.
- Trial name
- PneumoCAP (NCT03322670)
- Testing
- Signs of CAP and a positive chest X-Ray, Patients directly hospitalized, Control patients
- Where
- France
- Volunteers
- 412 people
- Sponsor
- CNGE Conseil
Pneumococcal Pneumonia, Influenza
The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine
The immunogenicity of simultaneous administration of quadrivalent influenza vaccine and pneumococcal vaccine was unknown. The purpose of present study is to compare the immunogenicity of simultaneous administration of influenza…
- Trial name
- NCT02592486
- Testing
- Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®, Sequential administration of Pneumovax NP® and Fluvic HA syringe®
- Where
- Japan
- Volunteers
- 162 people
- Sponsor
- Kameda Medical Center
Pneumonia, Pneumococcal
Evaluation of PCV Schedules in a Naive Population in Vietnam
The cost of pneumococcal conjugate vaccine use can be greatly reduced by making use of existing herd immunity to protect children against vaccine type pneumococci.
- Trial name
- NCT02961231
- Testing
- PCV 2p+1, PCV 3p+0, PCV 1p+1
- Where
- Vietnam
- Volunteers
- 18,652 people, healthy volunteers welcome
- Sponsor
- Nagasaki University
Pneumococcal Pneumonia
Targeting of Immune Response After Pneumococcal Vaccination
Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study aims to compare lymphocyte homing in pneumonia and in those receiving Pnc polysaccharide vaccine (PPV) or Pnc conjugate…
- Trial name
- PncHR (NCT01402245)
- Testing
- Pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine
- Where
- 4 sites in Finland
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Leukemia
Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients
The goal of this clinical research study is to see if Leukine(R) (sargramostim) improves the effectiveness of the pneumococcal vaccine, a medicine used to prevent pneumococcal pneumonia, in patients with chronic lymphocytic…
- Trial name
- NCT00323557
- Testing
- Sargramostim (GM-CSF), Pneumococcal Vaccine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Infections, Streptococcal
COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine
This is a study in a large number of healthy children less than 3 years old to measure the efficacy of GlaxoSmithKline (GSK) Biologicals' 10-valent pneumococcal conjugate candidate vaccine (Synflorix vaccine, or GSK1024850A) to…
- Trial name
- NCT00466947
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, Havrix, Engerix-B
- Where
- 22 sites in Argentina, Colombia and 1 more
- Volunteers
- 23,802 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumonia, Pneumococcal, Pneumococcal Infections
Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.
- Conditions
- Pneumonia, Pneumococcal, Pneumococcal Infections, 13-valent Pneumococcal Vaccine
- Trial name
- CAPITA (NCT00744263)
- Testing
- VACCINE: 13-valent pneumococcal conjugate vaccine
- Where
- 159 sites in Netherlands
- Volunteers
- 84,496 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Bacterial, Pneumococcal Infections
A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants
This is a Phase 2 clinical study evaluating AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of three different…
- Conditions
- Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
- Trial name
- NCT05412030
- Testing
- AFX3772, Prevnar 13, Prevnar 20
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 388 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, Pneumococcal Infections
Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years
Vaccination is a key strategy for preventing respiratory illnesses. Pneumococcal vaccination is recommended for all adults aged over 60 or 65 years (depending local guidelines) who have never received a pneumococcal vaccine or…
- Trial name
- NVX_PCV20 (NCT05767606)
- Testing
- NVX, PCV20
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Pneumococcal Infections, Pneumonia, Pneumococcal
Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae
This is a randomized, double-blind, placebo-controlled study. Eligible subjects will be randomized in a 1:1 ratio to receive GEN-004 with adjuvant or placebo. Each subject will receive up to 3 doses at 4 week intervals.
- Trial name
- NCT02116998
- Testing
- GEN-004 with Aluminum Hydroxide Adjuvant, Streptococcus pneumoniae inoculation
- Where
- United Kingdom
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Genocea Biosciences, Inc.
Pneumonia, Bacterial, Cancer
Impact of Pharmacist-led Educational Intervention on Pneumococcal Vaccination Rates in Cancer Patients
According to the World Health Organization (WHO), immunization; is defined as making a person immune or resistant to an infectious disease by applying a vaccine (1).
- Conditions
- Pneumonia, Bacterial, Cancer, Pneumococcal Infections
- Trial name
- NCT05229081
- Testing
- vaccine education
- Where
- Turkey (Türkiye)
- Volunteers
- 228 people
- Sponsor
- Hacettepe University
Pneumococcal Infections
A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria
A vaccine called Prevenar is already approved for use in China for vaccination of children younger than 6 years old against infections caused by Streptococcus pneumoniae.
- Trial name
- 6114A1-4000-CN (NCT01193582)
- Testing
- Prevenar
- Where
- 5 sites in China
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- Pfizer